Our Therapeutic Areas
Sandoz is a world leader in the production of quality and affordable products. It is one of the largest generic companies in the world. It offers a wide portfolio of high-quality molecules for the possibility of choosing the most suitable therapy in the field of Cardiovascular, Central nervous system, Gastroenterology, Infectious, Oncology, Orthopedic, Respiratory and Biosimilars.
Our broad portfolio is backed by a range of state-of-the-art technologies, formulations and devices, including prolonged-release and multiple-unit tablets, creams and gels, orodispersible films, transdermal patches, lyophilized products, implants and inhalers.1
Cardiology
Sandoz holds a leading position in generic cardiovascular medications.1
Central Nervous System
CNS disease significantly affects the patient's life, often affects his behavior and quality of life.
Gastroenterology
Sandoz offers options for the treatment of common gastrointestinal conditions.
Infectious
As the global leader in generic antibiotics, Sandoz plays a critical role in ensuring the sustainability of global healthcare systems: antibiotics are the cornerstone of healthcare today.2
Oncology
Cancer is one of the leading causes of death and places a significant and growing burden on healthcare systems around the world. With a leading global generic oncology portfolio of >50 products, from chemotherapy, via hormones and supportive care, to biologic.3
Orthopedic
Chronic pain ranks among the most prevalent medical conditions affecting humans, being among the 10 most prevalent diseases worldwide.4
Respiratory
Sandoz is well positioned for leadership in the fast-growing respiratory market given our strong portfolio and capabilities. At Sandoz, it is our purpose to improve the quality of treatment for asthma and chronic obstructive pulmonary disease, and to ease the suffering that seasonal allergies cause.5
Biosimilars
Sandoz, a Novartis division, is a pioneer and a global leader in biosimilars. We invest in research and development to improve the lives of patients and liberate healthcare resources through increased access to high-quality, affordable biologics.
Reference
- Sandoz. Our Work – Disease Areas [Online]. Cited 17 Dec 2021. Available from: https://www.sandoz.com/our-work/disease-areas
- Sandoz. Our Work – Disease Areas - Anti-Infectives [Online]. Cited 17 Dec 2021. Available from: https://www.sandoz.com/our-work/disease-areas/anti-infectives
- Sandoz. Our Work - Disease Areas - Biopharmaceuticals [Online]. Cited 17 Dec 2021. Available from: https://www.sandoz.com/our-work/biopharmaceuticals/sandoz-biosimilar-po…
- Sa, Katia Nunesa,*; Moreira, Larissab; Baptista, Abrahao Fontesc; Yeng, Lin Tchiad,e; Teixeira, Manoel Jacobsenb; Galhardoni, Ricardob,f; de Andrade, Daniel Ciampib,d Prevalence of chronic pain in developing countries: systematic review and meta-analysis, PAIN Reports: November/December 2019 - Volume 4 - Issue 6 - p e779 doi: 10.1097/PR9.0000000000000779
- Sandoz. Our Work - Disease Areas - Respiratory [Online]. Cited 28 Dec 2021. Available from: https://www.sandoz.com/our-work/disease-areas/respiratory